Evidence map›Paper›PMID 28940382›Full record

ReviewAlcoholism, clinical and experimental research2017

The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

Matthew B Pomrenze, Tracy L Fetterly, Danny G Winder, Robert O Messing

Abstract readReview
In one paragraph

Review in Alcoholism, clinical and experimental research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Synaptic Effects Induced by Alcohol.Current topics in behavioral neurosciences · 2025
    Review
  9. Article
  10. Mouse parasubthalamicbioRxiv : the preprint server for biology · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Synaptic effects of IL-1β and CRF in the central amygdala after protracted alcohol abstinence in male rhesus macaques.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew B PomrenzeInstitute for Neuroscience, the University of Texas at Austin, Austin, Texas.
Tracy L FetterlyDepartment of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, Tennessee.
Danny G WinderDepartment of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, Tennessee.
Robert O MessingInstitute for Neuroscience, the University of Texas at Austin, Austin, Texas.ORCID http://orcid.org/0000-0002-5345-4431
The University of Texas at Austin · USVanderbilt University · US

Funding

Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1M
Alcohol action on extended amygdala glutamate synapsesR37AA019455 · NIAAA · VANDERBILT UNIVERSITY · PI WINDER, DANNY G. · 2015 to 2024
$3.9M
Regulation of GABAA Receptors by PKC epsilon.R37AA013588 · NIAAA · ERNEST GALLO CLINIC AND RESEARCH CENTER · PI MESSING, ROBERT O. · 2003 to 2011
$3.7M
Regulation of GABAA Receptors by PKC epsilon.R01AA013588 · NIAAA · UNIVERSITY OF TEXAS AT AUSTIN · PI MESSING, ROBERT O. · 2002 to 2016
$1.9M
Alcohol action on extended amygdala glutamate synapsesR01AA019455 · NIAAA · VANDERBILT UNIVERSITY · PI WINDER, DANNY G. · 2010 to 2014
$1.8M
CRF neurons of the extended amygdala and alcohol drinkingR01AA026075 · NIAAA · UNIVERSITY OF TEXAS AT AUSTIN · PI MESSING, ROBERT O. · 2017 to 2021
$1.7M
NIAAA NIH HHS R01 AA013588NIAAA NIH HHS R01 AA019455NIAAA NIH HHS R01 AA026075NIAAA NIH HHS R37 AA013588NIAAA NIH HHS R37 AA019455NICHD NIH HHS U54 HD083211
6 · The paper itself

Abstract

Corticotropin releasing factor (CRF) is a neuropeptide that plays a key role in behavioral and physiological responses to stress. A large body of animal literature implicates CRF acting at type 1 CRF receptors (CRFR1) in consumption by alcohol-dependent subjects, stress-induced reinstatement of alcohol seeking, and possibly binge alcohol consumption. These studies have encouraged recent pilot studies of CRFR1 antagonists in humans with alcohol use disorder (AUD). It was a great disappointment to many in the field that these studies failed to show an effect of these compounds on stress-induced alcohol craving. Here, we examine these studies to explore potential limitations and discuss preclinical and human literature to ask whether CRFR1 is still a valid drug target to pursue for the treatment of AUD.

Indexed as

AlcoholismAnimalsCRF Receptor, Type 1HumansMolecular Targeted TherapyReceptors, Corticotropin-Releasing HormoneCRF Receptor, Type 1Receptors, Corticotropin-Releasing HormoneAlcohol CravingAlcohol SeekingAlcohol Use DisorderCorticotropin Releasing Factor Receptor Type 1Neuropeptide

Identifiers

PMID28940382
PMCPMC5711524
OpenAlexW2756719733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.